There is little information on the effects of H. pylori eradication in patients with a primary diagnosis of gastro-esophageal reflux disease (GERD).
Werner Schwizer and colleagues from University Hospital, Zurich, Switzerland, investigated the effect of H. pylori eradication in this group of patients.
70 patients with GERD took part in a randomized, placebo-controlled, double-blind study.
Patients were divided into 3 groups, with all patients receiving lansoprazole (to eradicate H. pylori) 30 mg twice daily for 10 days, followed by 30 mg once daily for 8 weeks.
|GERD-free interval period:|
H. pylori-positive: 54 days
H. pylori eradicated: 100
H. pylori-negative: 110
Patients infected with H. pylori received either antibiotics (clarithromycin 500 mg and amoxicillin 1000 mg twice daily) or placebo for the first 10 days.
Controls were patients not infected with H. pylori.
Patients were followed up for 6 months at 2-week intervals for GERD symptoms, and at the end of the study esophageal and gastric monitoring was repeated.
H. pylori-positive patients relapsed earlier (54 days) than patients in whom H. pylori had been eradicated (100 days). The H. pylori-negative control group relapsed after the longest period (110 days).
The time to relapse was also affected by esophagitis grade (no esophagitis 127 days, Grade III or IV esophagitis 18 days).
Werner Schwizer comments, "Our study has shown that the presence of H. pylori leads to a reduced disease-free interval, and, therefore, eradication therapy should be considered in patients with GERD."